文献速递心力衰竭与心肌病

口服镁剂与美国心衰退伍军人结局的关联

Oral magnesium and outcomes in US veterans with heart failure.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究基于54 696例心衰退伍军人(2001-2023年),其中低镁血症者中10 695例启动口服镁(中位剂量420 mg/天)。倾向评分匹配后分析显示,低镁血症患者口服镁与心衰住院或死亡风险降低相关(HR 0.91, 95%CI 0.86-0.97),而血镁正常者口服镁风险反而升高(HR 1.11, 95%CI 1.02-1.21)。

要点

  • 低镁血症心衰患者口服镁与心衰住院或死亡风险降低相关。
  • 血镁正常心衰患者口服镁与风险升高相关,提示不应常规补镁。

核心结论

  • 在心衰合并低镁血症患者中,口服镁治疗与心衰住院或死亡风险降低相关。

研究设计与样本

  • 回顾性队列研究,纳入54 696例心衰退伍军人(2001-2023年),其中低镁血症者10 695例启动口服镁(中位剂量420 mg/天)。
  • 采用倾向评分匹配构建低镁血症队列21 098例(治疗组10 549例)及血镁正常队列11 634例(治疗组5 817例),评估口服镁与一年结局的关联。

主要发现

  • 低镁血症队列中,未治疗组心衰住院或死亡发生率为21.7%,治疗组为20.1%(HR 0.91; 95%CI 0.86-0.97)。
  • 血镁正常队列中,未治疗组发生率为17.8%,治疗组为19.5%(HR 1.11; 95%CI 1.02-1.21)。
  • 样条回归显示血镁<1.5 mg/dL时HR较低,>1.8 mg/dL时HR较高,1.5-1.8 mg/dL之间无显著差异。

临床怎么用

  • 对心衰合并低镁血症患者,可考虑口服镁治疗以降低心衰住院或死亡风险。
  • 血镁正常的心衰患者不应常规补充口服镁。

局限性

  • 本研究为观察性研究,残余混杂可能影响结果。
  • 结论需未来临床试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Magnesium deficiency is associated with poor outcomes in patients with heart failure (HF), but less is known about the impact of oral magnesium therapy. This study aimed to examine the association of oral magnesium with outcomes in patients with HF and whether it depends on baseline serum magnesium. METHODS: Of 54 696 Veterans with HF (2001-2023) and hypomagnesemia (serum magnesium <1.7 mg/dL), 10 695 were initiated on oral magnesium (median dose, 420 mg/day). A propensity score-matched cohort of 21 098 patients (treated, n = 10 549) balanced on 71 baseline characteristics was assembled while remaining outcome-blinded. This process was repeated to assemble a matched cohort of 11 634 patients (treated, n = 5817) with normomagnesemia (serum magnesium, 1.7-2.3 mg/dL). Hazard ratios (HR) (95% confidence intervals [CIs]) for one-year outcomes associated with oral magnesium were estimated. RESULTS: In the hypomagnesemia cohort, HF hospitalization or death occurred in 21.7% of patients not receiving and 20.1% receiving oral magnesium (HR: 0.91; 95% CI: 0.86-0.97). Respective HRs (95% CIs) in subgroups with serum magnesium 1.6 (n = 5929), 1.3-1.5 (n = 11 293) and <1.3 (n = 3876) mg/dL were 0.99 (0.88-1.12), 0.91 (0.84-0.98; interaction P = .20), and 0.81 (0.71-0.93; interaction P = .03). Respective rates in the normomagnesemia cohort were 17.8% and 19.5% (HR: 1.11; 95% CI: 1.02-1.21). Spline regression analysis revealed that HRs were lower at serum magnesium <1.5 mg/dL, higher at >1.8 mg/dL, and not significant at 1.5-1.8 mg/dL. CONCLUSIONS: Oral magnesium therapy was associated with a lower risk of HF hospitalization or death in patients with HF and hypomagnesemia. Future clinical trials need to confirm these findings.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Yin, Costello, Fonarow, et al. Oral magnesium and outcomes in US veterans with heart failure. Eur Heart J. 2026. PMID: 41338273. doi:10.1093/eurheartj/ehaf881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。